News and Press Releases

Gilead and Kite Oncology  Present Important Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

– Real-World Evidence and New Clinical Analysis Support the Role of Trodelvy (sacituzumab govitecan-hziy) in Metastatic Breast Cancers – New Data Demonstrate Potential of Sacituzumab Govitecan in Small Cell Lung...

Category: Pharmaceutical
Posted: October 16, 2023

Kite’s CAR T-Cell Therapy Accepted for Use on the NHS in Scotland to Treat Aggressive Form of Blood Cancer

First CAR T-cell therapy for adult (26+) patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) reimbursed in Scotland 9 October 2023 -- London, UK -- Gilead Sciences...

Category: Pharmaceutical
Posted: October 9, 2023